Ankyrin Repeat-Containing Protein UACA: Potential Drug Target and Biomarker

Target Name: UACA

NCBI ID: G55075

UACA

Other Name(s): Uveal autoantigen with coiled-coil domains and ankyrin repeats | Uveal autoantigen with coiled-coil domains and ankyrin repeats, transcript variant 1 | Uveal autoantigen with coiled-coil domains and ankyrin repeats, transcript variant 2 | NUCLING | Uveal autoantigen with coiled coil domains and ankyrin repeats | nuclear membrane binding protein | Uveal autoantigen with coiled-coil domains and ankyrin repeats (isoform 2) | Uveal autoantigen with coiled-coil domains and ankyrin repeats (isoform 1) | KIAA1561 | UACA variant 2 | uveal autoantigen with coiled-coil domains and ankyrin repeats | Nuclear membrane binding protein | UACA variant 1 | UACA_HUMAN

Ankyrin Repeat-Containing Protein UACA: Potential Drug Target and Biomarker

Uveal autoantigen with coiled-coil domains and ankyrin repeats (UACA) is a protein that is expressed in the uveal tissue, including the eye and the eyelid. It is a member of the superfamily of coiled-coil proteins, which are a type of protein that can form covalent bonds between amino acids. UACA is unique because it contains ankyrin repeats, which are a specific type of protein structure that is characterized by the presence of a specific repeat unit composed of the amino acids GXXG YYY and a terminal phosphate group.

UACA is expressed in a variety of tissues throughout the body, including the eye, the skin, and the heart. It is involved in the regulation of cell growth, differentiation, and inflammation. UACA has also been shown to play a role in the development and progression of a variety of diseases, including cancer, autoimmune diseases, and neurodegenerative diseases.

One of the potential reasons for the interest in UACA is its potential as a drug target. Its unique structure and the presence of ankyrin repeats make it an attractive target for small molecules that can modulate its activity. Several studies have shown that UACA can be targeted by small molecules, including inhibitors of tyrosine kinase activity and inhibitors of the protein kinase CKL.

In addition to its potential as a drug target, UACA is also a potential biomarker for a variety of diseases. Its expression is often abnormal in a variety of diseases, including cancer, autoimmune diseases, and neurodegenerative diseases. Therefore, its levels may be a useful indicator of disease status in these conditions.

Overall, UACA is a protein that is expressed in a variety of tissues and is involved in the regulation of cell growth, differentiation, and inflammation. Its unique structure, including the presence of ankyrin repeats, makes it an attractive target for small molecules, and its expression is often abnormal in a variety of diseases, making it a potential biomarker. Further research is needed to fully understand the role of UACA in disease and to develop effective treatments.

Protein Name: Uveal Autoantigen With Coiled-coil Domains And Ankyrin Repeats

Functions: Regulates APAF1 expression and plays an important role in the regulation of stress-induced apoptosis. Promotes apoptosis by regulating three pathways, apoptosome up-regulation, LGALS3/galectin-3 down-regulation and NF-kappa-B inactivation. Regulates the redistribution of APAF1 into the nucleus after proapoptotic stress. Down-regulates the expression of LGALS3 by inhibiting NFKB1 (By similarity)

The "UACA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UACA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets